Mahmoud Abdelrahman Mohamed
Faculty of Medicine, Menoufia University, Menoufia, Egypt.
Curr Med Res Opin. 2023 Feb;39(2):249-257. doi: 10.1080/03007995.2022.2135838. Epub 2022 Oct 22.
Since there is now no medication available that has been approved by the US Food and Drug Administration, alopecia areata (AA) is an autoimmune condition that has a detrimental impact on individuals. Recent clinical trials using baricitinib demonstrated that it may be effective in treating AA. This meta-analysis was done to evaluate the effectiveness and safety of baricitinib in comparison to placebo.
Author looked through Scopus, Web of Science, Cochrane Library, PubMed, for all published, randomized, clinical trials.
This meta-analysis included 1282 participants from two citations (reporting three stand-alone studies). In term of SALT score, baricitinib significantly outperformed placebo; MD = -34.07, 95% CI [-37.90, -30.23], < .00001. Additionally, the proportion of patients in the baricitinib group that attained SALT ≤ 20 was significantly higher than in the placebo group; RR = 6.41, 95% CI [4.57, 8.98], < .00001. The results of the safety analysis revealed no significant differences between the baricitinib and placebo groups for any of the outcomes with the exception of acne, which was significantly higher in the placebo group when compared to the baricitinib group (RR= 4.79, 95% CI [2.38, 9.66], .0001).
When compared to placebo, baricitinib is an effective and well-tolerated medication for the treatment of AA.
由于目前尚无经美国食品药品监督管理局批准的治疗斑秃（AA）的药物，斑秃是一种对个体有不利影响的自身免疫性疾病。最近使用巴瑞替尼的临床试验表明，它可能对治疗斑秃有效。进行这项荟萃分析以评估巴瑞替尼与安慰剂相比的有效性和安全性。
作者在Scopus、科学网、考克兰图书馆、PubMed中检索了所有已发表的随机临床试验。
该荟萃分析纳入了来自两篇文献（报告三项独立研究）的1282名参与者。就SALT评分而言，巴瑞替尼显著优于安慰剂；MD = -34.07，95%CI[-37.90，-30.23]，P <.00001。此外，巴瑞替尼组中SALT≤20的患者比例显著高于安慰剂组；RR = 6.41，95%CI[4.57，8.98]，P <.00001。安全性分析结果显示，除痤疮外，巴瑞替尼组和安慰剂组在任何结局方面均无显著差异，与巴瑞替尼组相比，安慰剂组的痤疮发生率显著更高（RR = 4.79，95%CI[2.38，9.66]，P =.0001）。
与安慰剂相比，巴瑞替尼是一种治疗斑秃有效且耐受性良好的药物。
